Today: 17 May 2026
Browse Category

NASDAQ:IOVA 3 November 2025 - 23 December 2025

Iovance Biotherapeutics (IOVA) Stock News Today: Barclays Raises Target, Short-Interest Pressure, and 2026 Catalysts (Dec. 23, 2025)

Iovance Biotherapeutics (IOVA) Stock News Today: Barclays Raises Target, Short-Interest Pressure, and 2026 Catalysts (Dec. 23, 2025)

Iovance Biotherapeutics shares jumped 12.1% to close at $2.78 on Dec. 22, with pre-market trading near $2.80. Short interest stands at 33.4% of the float, or about 118.94 million shares, according to MarketBeat. Barclays raised its price target to $10 and kept an Overweight rating. Iovance also announced inducement stock options for four new employees at a $2.46 exercise price.
23 December 2025
Iovance Biotherapeutics (IOVA) Q3 2025: Revenue Climbs ~13% to ~$68M; Gross Margin Hits 43%, Guidance Reaffirmed — November 6, 2025

Iovance Biotherapeutics (IOVA) Q3 2025: Revenue Climbs ~13% to ~$68M; Gross Margin Hits 43%, Guidance Reaffirmed — November 6, 2025

Iovance Biotherapeutics reported Q3 2025 revenue of $67.5 million, up 13% sequentially but below analyst expectations, and a net loss of $91.3 million, or $0.25 per share. Gross margin rose to 43%. Management reaffirmed full-year revenue guidance of $250–$300 million. Over 80 U.S. treatment centers are now active, and cash reserves totaled $307 million at quarter’s end.
6 November 2025
···
Iovance Biotherapeutics (IOVA): TIL Cancer Breakthrough or Biotech Bust?

Iovance Biotherapeutics (IOVA): TIL Cancer Breakthrough or Biotech Bust?

Iovance shares traded near $2.00 on Nov. 3, 2025, with a market cap around $700 million after plunging 70% year-to-date. The company’s Amtagvi, the first FDA-approved TIL therapy for advanced melanoma, also secured Health Canada approval. Interim Phase 2 data showed a 25.6% response rate for lifileucel in advanced NSCLC. Iovance will hold its Q3 earnings call on Nov. 6.
3 November 2025

Stock Market Today

  • Understanding Tax-Loss Harvesting Amid Stock Market Gains
    May 16, 2026, 7:47 PM EDT. Tax-loss harvesting is gaining traction as the stock market surges, offering investors a strategy to offset capital gains by selling investments at a loss. This technique can reduce taxable income and boost after-tax returns. Wall Street professionals are increasingly adopting this approach to optimize portfolios in a high-gain environment. The method involves careful timing and selection of assets to comply with tax regulations while maintaining market positions. As tax considerations grow in importance, investors seek effective strategies like tax-loss harvesting to manage their liabilities amidst fluctuating markets.

Latest articles

Joby Aviation Slides Monday With Air-Taxi in Focus

Joby Aviation Slides Monday With Air-Taxi in Focus

17 May 2026
Joby Aviation shares closed Friday at $10.36, down 2.6% for the day and 4.7% for the week. CEO JoeBen Bevirt-linked trusts sold over 421,000 shares under a preset 10b5-1 plan, filings showed. The stock traded between $10.04 and $10.58 during a volatile week. Broader markets and eVTOL sector peers also declined.
ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus

ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus

17 May 2026
ImmunityBio closed at $7.97 Friday, down 2.2% after announcing exclusive U.S. rights to Japan BCG Laboratory’s Tokyo-172 strain for bladder cancer therapy. The Tokyo strain remains investigational in the U.S. and is not FDA-approved. Nasdaq was closed for the weekend; the next trading session is Monday. ImmunityBio’s Q1 product revenue rose to $44.2 million with $380.9 million in cash and securities.
Infleqtion Stock Just Took a Hit After Record Revenue — What Could Move INFQ Next

Infleqtion Stock Just Took a Hit After Record Revenue — What Could Move INFQ Next

17 May 2026
Infleqtion Inc. shares fell 10.95% to $12.44 Friday, capping a rough week for quantum tech stocks. The company reported a first-quarter net loss of $30.3 million on $9.5 million in revenue, with 85% from government contracts. Infleqtion launched a new RF sensing platform and raised its 2026 revenue outlook, but warned of continued operating losses.
Synopsys Shares Dropped for the Week, Looking to May 27 for Direction

Synopsys Shares Dropped for the Week, Looking to May 27 for Direction

17 May 2026
Synopsys shares fell 1.49% Friday to $502.42, ending the week down 2.72% amid a broad tech selloff and news that Coatue Management cut its stake by 54%. The Nasdaq Composite dropped 1.54% Friday, while the Philadelphia semiconductor index slid 4%. Synopsys will report fiscal Q2 results after the market closes on May 27. Wells Fargo and Citigroup raised their price targets for the stock earlier in the week.
Go toTop